Adrenocortical Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Adrenocortical Carcinoma (ACC) Market Outlook

Thelansis’s “Adrenocortical Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adrenocortical Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Adrenocortical Carcinoma (ACC) Overview

Adrenocortical carcinoma (ACC) is rare cancer that affects the adrenal gland and primarily affects individuals in early adulthood and between the ages of 40-50. Women are more commonly affected, comprising 55-60% of cases. The majority of ACC cases are of sporadic origin. However, they can also develop as part of familial diseases such as Beckwith-Wiedeman syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia (MEN), and familial adenomatous polyposis (FAP). There are three main clinical presentations of ACC: hormone excess symptoms and signs in 40-60% of patients, non-specific symptoms due to local tumor growth such as abdominal or flank pain, abdominal fullness, or early satiety in a third of patients. Although the specific genetic alterations involved in ACC development are currently unknown, chromosomal abnormalities have been identified in hereditary neoplasia syndromes. The Wnt/β-catenin constitutive activation and insulin growth factor 2 (IGF2) overexpression are the most important implicated genetic pathways. The protein steroidogenic factor 1 (SF1) plays a significant role in adrenal development and is often overexpressed in ACC. Treatment of ACC requires a multidisciplinary approach, with initial surgical resection in limited disease (stages I, II, and occasionally III). Mitotane (1,1-dichloro-2(o-chlorophenyl)-2-(p-chlorophenyl)ethane [o,p’DDD]) is the only currently available adrenolytic medication, achieving an overall response rate of approximately 30%. The five-year survival rate for ACC varies depending on the presentation stage, with the ENSAT system reporting rates of 82% for stage I, 61% for stage II, 50% for stage III, and 13% for stage IV.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Adrenocortical Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034